Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

Схожие документы

• Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
  по: Nattinger, Ann Butler, et al.
  Опубликовано: (2015)
• Temporal Trends and Regional Variation in the Utilization of Low-Value Breast Cancer Care: Has the Choosing Wisely Campaign Made a Difference?
  по: Neuner, Joan, et al.
  Опубликовано: (2019)
• The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees
  по: Neuner, Joan M., et al.
  Опубликовано: (2015)
• Socioeconomic Disparities in Mortality Among Women With Incident Breast Cancer Before and After Implementation of Medicare Part D
  по: Nattinger, Ann B., et al.
  Опубликовано: (2017)
• Re-examining the Relationship of Breast Cancer Hospital and Surgical Volume to Mortality: An Instrumental Variable Analysis
  по: Pezzin, Liliana E., et al.
  Опубликовано: (2015)